Hi @Wilba32
you are going to like this.
I raised medac's November '23 publication to the CEO and others after the AGM, and they are very much aware of it, along with Novartis/ Incyte efforts to get into the pediatric market.
They see the ruxolitinib-resistant aGVHD in the same way as the researchers here. But MSB is taking a different approach in preparation for the market - it's all about reference pricing, and that's a very good reason why MSB persists with the USA. MSB could go to Europe tomorrow morning, but sees everything that's being done right now as being done for a very good reason.
Cheers
Getting exciting, eh
Cell Therapy News/Articles, page-17353
-
- There are more pages in this discussion • 468 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.035(2.94%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $5.183M | 4.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 191274 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 46965 | 11 |
View Market Depth
| Last trade - 15.15pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |